Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Inadequacies in current early-stage lung cancer treatment revealed

Findings conducted by researchers from Tohoku University and Tohoku University Hospital have revealed why some existing cancer treatments are ineffective in tackling the early-stages of lung cancer.

A team led by Professor Tetsuya Kodama investigated the ability of anti-cancer agents to affect early-stage lung metastatic tumours.

The team developed a mouse model of lung metastasis that can produce lesions (less than 100 μm), which current clinical imaging had been unable to detect.

Micro X-ray CT and histopathology were used to analyse the lungs.

The small arteries were shown to be obstructed by tumour cells, which significantly reduces the total vessel length, volume, and number of vessel branches in the lung.

The compromised arteries prevent anti-cancer agents with low-molecular weights from being sufficiently administered to a tumour.

Past animal experiments have shown that the enhanced permeability and retention (EPR) effect occurs when new tumour blood vessels are formed.

This then enables the extravasation of certain size molecules (100-200 nm) to accumulate in tumours, more so than normal tissue.

Experiments undertaken by Professor Kodama's team indicate that fluorescent dye encapsulated liposome (diameter 145 mm) are not present around lesions at the early stage of tumour development.

This means that high-molecular weight anti-cancer agents also cannot be considered an effective haematogenous drug delivery method for the treatment of lung cancer at the early stage.

Surgery followed by a course of chemotherapy has been the mainstream treatment for early-stage lung cancer for some time.

However, based on this research, Professor Kodama suggests that "these findings indicate the need for new drug delivery methods to replace conventional systemic chemotherapy and the development of new therapies for lung cancer."

Source: Tohoku University

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation